In Brief: Novo Nordisk's Norditropin
Novo Nordisk's Norditropin: Ten-day temporary restraining order is issued June 14 on the sale of the company's recently approved human growth hormone product while Brooklyn federal court Judge Constance Baker Motley considers Genentech's motion for preliminary injunction in its patent infringement suit against the Danish firm. Novo had planned to begin shipping Norditropin by June 19. Genentech plans to seek similar restraints against the marketing of BTG's BioTropin approved on May 25...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth